Wandercraft Unveils Eve: A New Dawn for Hands-Free Mobility in Spinal Cord Injury Community

NEW YORK, NY – [Date of publication, e.g., October 26, 2023] – In a landmark development set to redefine personal mobility for individuals with spinal cord injuries, Wandercraft, a pioneer in advanced robotics, has officially announced the U.S. commercial launch of Eve. Hailed as the world’s first FDA-cleared self-balancing personal exoskeleton, Eve promises to unlock unprecedented hands-free upright mobility for eligible adults, irrespective of their neurological injury level. This momentous launch represents a significant leap forward, offering wheelchair users a revolutionary option to stand, walk, and interact with their environment with newfound independence and dignity.

Eve’s introduction to the U.S. market follows years of rigorous development, extensive clinical trials, and a comprehensive regulatory approval process. Its core innovation lies in its sophisticated self-balancing technology, powered by advanced physical artificial intelligence (AI). Unlike traditional exoskeletons that often necessitate the use of crutches or walkers for stability, Eve empowers users to maintain their balance autonomously, freeing their hands for a multitude of daily activities – from preparing meals and opening doors to carrying objects and engaging in social interactions at eye level. This distinction is not merely a convenience; it is a fundamental shift in how individuals with spinal cord injuries can navigate and participate in the world around them.

The commercial rollout marks the culmination of Wandercraft’s vision to transform assistive technology from a tool of basic mobility into an enabler of holistic well-being. The company has established a robust infrastructure to support prospective users every step of the way, encompassing clinical evaluation, personalized fitting, comprehensive training programs, and ongoing technical and reimbursement support. This holistic approach underscores Wandercraft’s commitment not just to technological innovation, but to ensuring that Eve seamlessly integrates into the lives of those it is designed to serve.

Main Facts

Wandercraft’s Eve exoskeleton is a groundbreaking medical device that has achieved U.S. commercial availability following its pioneering FDA clearance. Its central promise is to provide eligible adults living with spinal cord injuries (SCI) the ability to achieve hands-free, upright mobility. This eligibility is remarkably broad, extending to individuals at any neurological level of spinal cord injury, provided they can safely operate the device’s manual controller and have no contraindications listed in the User Manual. This expansive criteria stands in stark contrast to many previously cleared exoskeletons, which often imposed stricter limitations based on the injury level, thereby significantly enlarging the potential user population.

The defining characteristic of Eve is its self-balancing technology, a feature that sets it apart from conventional exoskeletons. This advanced system, driven by what Wandercraft refers to as "physical AI," eliminates the need for crutches or walkers to maintain stability. For users, this translates into an unparalleled level of freedom and functionality. With hands free, individuals can perform a wide array of daily living activities that were previously challenging or impossible while upright, such as reaching for items on a shelf, carrying groceries, engaging in food preparation, or simply shaking hands and hugging loved ones without the impedance of assistive devices.

The path to acquiring an Eve exoskeleton is meticulously structured to ensure optimal user experience and safety. It commences with a thorough clinical evaluation, followed by a trial period to assess suitability and user comfort. Upon a successful trial and receipt of a physician’s order, each Eve unit is individually fitted and custom-manufactured to the user’s specific anthropometric measurements. This customization is critical for both comfort and performance. Following delivery, users undergo a personalized training program delivered by the Wandercraft team, ensuring they are proficient and confident in operating their new mobility device. Crucially, this support extends beyond delivery, with ongoing service and assistance available to users as they integrate Eve into their daily routines. Wandercraft emphasizes that Eve is designed to complement, rather than replace, a wheelchair, offering users an additional, powerful mobility option for moments when they choose to be upright.

Chronology of Innovation and Commercialization

The journey of Eve from concept to commercial reality is a testament to persistent innovation and strategic development within the field of rehabilitation robotics. Wandercraft has dedicated years to the intricate development of the underlying robotics and artificial intelligence that power Eve’s unique self-balancing capabilities. This extensive research and development phase focused on creating a device that could not only support upright mobility but do so autonomously and safely, liberating users’ hands.

A pivotal milestone in this chronology was the attainment of FDA clearance for Eve. While the specific date of clearance isn’t provided in detail, its significance is underscored by CEO Matthieu Masselin’s statement: "FDA clearance showed that Eve was ready to move forward." This regulatory approval validated the safety and efficacy of the device, paving the way for its introduction to the U.S. market. The FDA’s decision to clear Eve without restrictions based on the neurological level of spinal cord injury was a critical acknowledgment of the breadth and depth of the safety data, clinical evidence, and usability testing Wandercraft had diligently compiled.

Leading up to the commercial launch, Wandercraft also prioritized the generation and publication of robust clinical evidence to support the transition to personal use. New peer-reviewed research examining how individuals with tetraplegia and high paraplegia, along with their companions, could be trained to use a self-balancing exoskeleton, was published in the Journal of Visualized Experiments (JoVE). This publication demonstrated the feasibility and safety of Eve for personal integration. Concurrently, additional research findings were presented at the Academy of Spinal Cord Injury Professionals (ASCIP) Annual Meeting on September 8th, further reinforcing Eve’s efficacy in supporting safe, hands-free assisted walking with high user satisfaction and a low adverse-event rate.

The commercial launch itself, celebrated at Cure in New York City in conjunction with United Spinal Association’s 80th-anniversary event, marks the latest and most significant step in Eve’s timeline. This event brought together a diverse group of stakeholders, including individuals with SCI, clinicians, researchers, policymakers, and Wandercraft leaders, highlighting the broad impact and collaborative spirit behind the device’s introduction. Concurrently with the launch, Wandercraft solidified key strategic partnerships crucial for nationwide distribution and support. These include National Seating & Mobility (NSM) as the exclusive Complex Rehabilitation Technology (CRT) distribution partner, Good Shepherd Rehabilitation as a Center of Excellence and regional partner, and USVetServ as an authorized distributor for U.S. Department of Veterans Affairs facilities. Looking ahead, Wandercraft anticipates expanding its network of access locations, further broadening Eve’s reach and availability to those who can benefit from its transformative technology.

Supporting Data: The Pillars of Eve’s Promise

Eve’s potential to revolutionize mobility is built upon a foundation of cutting-edge technology, comprehensive clinical evidence, and a meticulously crafted access and support system.

Technological Ingenuity: Physical AI and Self-Balancing

At the heart of Eve’s innovation is its "physical AI" and self-balancing technology. Unlike previous generations of exoskeletons that acted more as rigid frames requiring external support (like crutches), Eve’s system continuously senses and analyzes the user’s movements, environment, and balance. It employs complex algorithms and robotic actuators to make real-time micro-adjustments to its posture and gait, maintaining equilibrium without user intervention. This dynamic stability mimics the natural human balance system, allowing for fluid, intuitive movement. The implications of this are profound: users are not merely walking; they are interacting with their surroundings, capable of bending, reaching, and performing multi-tasking actions that demand full use of their upper limbs. This hands-free capability transforms the exoskeleton from a mobility aid into an integrated extension of the user, facilitating genuine engagement with the world.

Expanded Eligibility: A Paradigm Shift

One of the most significant breakthroughs Eve brings is its eligibility for adults with spinal cord injuries at any neurological level. This is a dramatic departure from the limitations of many earlier exoskeletons, which often required a certain level of intact motor function or sensation to operate safely. Wandercraft’s ability to secure FDA clearance for such a broad population underscores the robustness of its safety data, the extensive clinical evidence gathered, and the thorough usability testing conducted. It means that individuals with higher-level injuries, such as tetraplegia, who previously had limited options for upright mobility, can now potentially benefit from Eve. This inclusivity is a powerful testament to the device’s inherent stability and the intuitive nature of its control system, opening doors for a much larger segment of the SCI community.

Rigorous Clinical Validation

The commercial launch of Eve is firmly underpinned by compelling clinical research, ensuring its efficacy and safety for personal use.

JoVE Study: Training for Personal Use: A pivotal study published in the Journal of Visualized Experiments (JoVE) focused on the practical application of Eve for individuals with tetraplegia and high paraplegia. This research explored how these individuals, along with their companions (who play a crucial role in daily support), could be trained to effectively use the self-balancing exoskeleton in a personal setting. Among the initial 16 participants who completed the study protocol, all successfully achieved the performance goals for key mobility assessments, including the Timed Up and Go test and the 6-Minute Walk Test, demonstrating significant functional improvement. Crucially, 15 out of 16 participants achieved the donning goal after just four training sessions, and all achieved the doffing goal, highlighting the device’s learnability and ease of use. The study reported no serious adverse events among the participants, reinforcing Eve’s safety profile during the training and usage phases. This research is particularly significant because it moved beyond merely proving someone could stand or walk in an exoskeleton, to demonstrating that individuals with high-level SCI could learn to use it for functional tasks relevant to personal, everyday life, often with the support of a companion.
ASCIP Presentation: Safety and Satisfaction: Further evidence was presented at the Academy of Spinal Cord Injury Professionals (ASCIP) Annual Meeting. This research detailed findings from the first 16 participant pairs in Wandercraft’s pivotal study conducted at the James J. Peters VA Medical Center and Kessler Foundation. The results unequivocally showed that Eve facilitated safe, hands-free assisted walking for individuals with spinal cord injury, maintaining a remarkably low adverse-event rate. Participants not only performed key mobility tasks but also engaged in various activities of daily living with a high perceived sense of safety, reported high user satisfaction, and found the training process to be straightforward and accessible. These findings collectively establish Eve as a reliable and user-friendly solution for hands-free upright mobility.

Facilitating Daily Living and Social Interaction

The hands-free capability afforded by Eve transcends mere physical movement; it profoundly impacts the quality of daily living and social interaction. Imagine the simple yet profound acts: reaching for a spice jar while cooking, carrying a plate to the table, opening a door for oneself or a guest, or holding a child’s hand. These seemingly small actions contribute immensely to independence and self-sufficiency. Beyond the practical, Eve enables users to engage in social settings at eye level, fostering more natural and equitable interactions. This ability to stand tall and move freely can significantly boost confidence, reduce feelings of isolation, and enhance overall psychological well-being.

Comprehensive Access and Reimbursement Ecosystem

Recognizing that advanced technology must be accessible, Wandercraft has established a robust ecosystem for trial, access, and reimbursement. A dedicated access team assists users and their care providers in navigating the complexities of benefits, documentation, reimbursement claims, and coordination with clinicians and payers. This comprehensive support is vital, given the specialized nature of the device.

Medicare Coverage: For eligible individuals meeting medical necessity requirements, Medicare provides coverage for qualifying personal exoskeletons. These devices are classified as custom-fitted orthoses under the Healthcare Common Procedure Coding System (HCPCS) billing code K1007, subject to individual coverage criteria. This established reimbursement pathway is crucial for making Eve a viable option for many.
Strategic Distribution Partnerships:
- National Seating & Mobility (NSM): As Wandercraft’s exclusive Complex Rehabilitation Technology (CRT) distribution partner, NSM plays a critical role. With a vast network of over 180 locations, NSM will facilitate evaluations, provide education, manage access, and oversee delivery. CRT providers are essential in connecting users with the specialized clinicians, Assistive Technology Professionals (ATPs), payers, and other experts necessary for navigating complex mobility care, ensuring a seamless transition from prescription to personal use.
- Good Shepherd Rehabilitation: This institution has been designated a Wandercraft Center of Excellence. Building on their deep expertise with Wandercraft’s Atalante X exoskeleton, Good Shepherd will serve as the exclusive Eve partner in Pennsylvania’s Lehigh Valley. Their Hyland Center will offer a dedicated space for eligible users to learn about and experience the technology, reinforcing the importance of specialized clinical support.
- USVetServ: To serve the veteran community, USVetServ, a Service-Disabled Veteran-Owned Small Business, will act as an authorized independent distributor for Eve and Atalante X across U.S. Department of Veterans Affairs medical centers and other VA facilities nationwide. This partnership ensures that veterans, a demographic often disproportionately affected by SCI, have dedicated access to this advanced mobility solution.

This multi-faceted approach to distribution and support underscores Wandercraft’s commitment to not only developing groundbreaking technology but also ensuring it reaches those who need it most, supported by expert guidance every step of the way.

Official Responses: Voices of Innovation and Experience

The launch of Eve has elicited powerful statements from key figures involved in its creation and testing, highlighting both the technical achievement and its profound human impact.

Matthieu Masselin, Co-founder and CEO of Wandercraft

Matthieu Masselin articulated the company’s journey and ethos, stating, “FDA clearance showed that Eve was ready to move forward. Today is about making it a reality for the people we built it for.” This quote captures the transition from regulatory triumph to tangible impact. Masselin emphasized the long-term dedication to engineering: “We have spent years developing the robotics, but our breakthroughs only matter when we’re able to better connect people to the world around them.” He further highlighted the comprehensive support system built around Eve, ensuring users are never left unsupported: “That’s why we built an infrastructure that supports people every step of the way, from evaluation and fitting to reimbursement, training, and ongoing service.” His words reflect a vision where technology serves to empower individuals and enhance human connection.

Caroline Laubach, Wandercraft Test Pilot

The perspective of a direct beneficiary offers invaluable insight into Eve’s transformative potential. Caroline Laubach, a Wandercraft test pilot, shared her personal experience: “With Eve, being upright isn’t just about standing. It’s about having the freedom to use my hands, move through my home, and connect with people in a new way.” Her statement underscores the device’s ability to facilitate not just physical mobility, but also a deeper sense of autonomy and social engagement. Laubach eloquently expressed the emotional impact, adding, “Those everyday moments bring me so much joy. What makes this milestone especially meaningful is knowing that more people will now have the chance to experience Eve for themselves and find that same joy in their own way.” Her testimony serves as a powerful validation of Eve’s design philosophy and its capacity to enhance quality of life.

Gail Forrest, PhD, Director at Kessler Foundation

Dr. Gail Forrest, a leading researcher involved in Eve’s clinical trials, provided a crucial scientific perspective on the significance of the research. “What is important about this work is that we evaluated more than whether someone could stand or walk in an exoskeleton,” she noted. “We examined whether people with high-level spinal cord injuries and their companions could learn to use a self-balancing exoskeleton and perform functional tasks relevant to personal use.” This statement highlights the rigorous and patient-centric nature of the studies, focusing on real-world applicability. Dr. Forrest concluded by emphasizing the critical link between research and practical implementation: “Commercial availability is an important next step toward translating that clinical work into carefully supported use in everyday life.” Her comments reinforce the credibility of Eve’s scientific foundation and its readiness for broader adoption.

Partners in Progress

While not directly quoted, the involvement of key partners like National Seating & Mobility, Good Shepherd Rehabilitation, and USVetServ signifies their strong endorsement and commitment to Eve’s success. Their participation demonstrates a shared belief in the device’s potential and a readiness to integrate it into existing care pathways for individuals with SCI. The celebration event in New York City, co-presented with the United Spinal Association, further underscores the device’s importance to the wider disability advocacy community, highlighting a collective hope for improved independence and inclusion.

Implications: A Future Reshaped by Hands-Free Mobility

The commercial launch of Wandercraft’s Eve is more than just the introduction of a new medical device; it heralds a new era for individuals with spinal cord injuries, with far-reaching implications across personal well-being, healthcare, and the broader field of assistive technology.

Transformative Impact on Quality of Life

The most immediate and profound implication of Eve is its potential to dramatically enhance the quality of life for its users. Hands-free upright mobility offers a cascade of physical, psychological, and social benefits:

Physical Health: Regular standing and walking can significantly improve bone density, reduce muscle spasticity, enhance circulation, improve bowel and bladder function, and decrease the risk of pressure ulcers—common secondary complications of SCI.
Psychological Well-being: The ability to stand tall, make eye contact, and move independently can profoundly boost self-esteem, reduce feelings of dependence, and combat depression and anxiety often associated with mobility limitations. The joy expressed by test pilot Caroline Laubach underscores this emotional uplift.
Social Inclusion: Interacting at eye level fundamentally changes social dynamics, fostering more natural and inclusive engagements in family, work, and community settings. It enables participation in activities previously inaccessible, such as standing at a concert, reaching for items in a grocery store, or playing with children while standing.
Increased Independence: By freeing the hands, Eve empowers users to perform a wider array of daily tasks autonomously, reducing reliance on caregivers for certain activities and enhancing overall self-sufficiency.

Future of Assistive Technology and Rehabilitation

Eve’s self-balancing "physical AI" represents a significant leap in assistive technology, pointing towards a future where devices are increasingly intelligent, autonomous, and integrated with human physiology.

Shift Towards Autonomy: This technology could inspire further research and development in smart prosthetics and orthotics, pushing the boundaries of what assistive devices can do without constant human intervention or cumbersome external aids.
Influence on Robotics and AI: The breakthroughs achieved in Eve’s development will likely contribute to advancements in general-purpose robotics and AI, with potential applications extending beyond rehabilitation into industrial automation, service robotics, and even space exploration, where stable, autonomous bipedal movement is crucial.
Rehabilitation Paradigms: The success of Eve and the supporting research may lead to new rehabilitation protocols and training methodologies that focus more on integrating advanced robotic aids into functional daily living rather than just clinical exercise.

Economic and Healthcare System Impact

While the initial investment in such advanced technology is significant, the long-term economic and healthcare implications could be positive.

Reduced Healthcare Costs: By mitigating secondary complications of SCI, Eve could lead to a reduction in hospitalizations, physician visits, and the need for medication, thereby lowering long-term healthcare expenditures.
Productivity and Participation: Greater independence and mobility can enable individuals to return to work, pursue education, and engage more fully in economic and social life, contributing to the broader economy.
Market Growth: The success of Eve is likely to stimulate innovation and competition in the market for advanced rehabilitation technologies, leading to further advancements and potentially more affordable solutions in the future. The establishment of clear reimbursement pathways, as seen with Medicare, is vital for driving this market growth and ensuring accessibility.

Challenges and Ongoing Evolution

Despite its groundbreaking nature, the widespread adoption of Eve will face challenges.

Cost and Reimbursement: While Medicare coverage is a positive step, ensuring broad and consistent reimbursement across all insurers remains an ongoing effort. The initial cost of such a sophisticated device can be a barrier for many.
User Adaptation and Training: Although designed for ease of use, integrating Eve into daily life requires dedicated training and adaptation, and continuous support infrastructure is essential.
Scaling Distribution: Expanding the network of clinical evaluation centers and distribution partners, like NSM and Good Shepherd, is crucial for reaching the entire eligible population across the U.S.
Continuous Improvement: Ongoing research and development will be necessary to refine the technology, address user feedback, and potentially expand its capabilities or reduce its footprint.

In conclusion, Wandercraft’s Eve exoskeleton represents a monumental step forward in empowering individuals with spinal cord injuries. By blending advanced robotics with intelligent AI, it offers not just a means to move, but a gateway to greater independence, dignity, and participation in the fullness of life. Its commercial launch is not merely a news item; it is a beacon of hope, marking a new era where the boundaries of personal mobility are continually redefined. To learn more about Eve or request an evaluation, interested individuals are directed to the Wandercraft website at https://www.wandercraft.eu/form.